What is HC Wainwright’s Forecast for AMLX Q1 Earnings?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings estimates for Amylyx Pharmaceuticals in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst A. Fein expects that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.35) EPS and Q4 2027 earnings at ($0.32) EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38).

AMLX has been the subject of several other research reports. Guggenheim increased their target price on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Tuesday. Citigroup upped their price target on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, October 15th. Stifel Nicolaus set a $45.00 price target on Amylyx Pharmaceuticals in a report on Thursday. Finally, Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Amylyx Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $44.14.

Amylyx Pharmaceuticals Stock Performance

NASDAQ AMLX opened at $27.62 on Friday. Amylyx Pharmaceuticals has a twelve month low of $10.83 and a twelve month high of $41.14. The stock has a market capitalization of $3.08 billion, a PE ratio of -19.31 and a beta of -0.09. The stock has a 50-day simple moving average of $30.15 and a 200 day simple moving average of $20.35.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMLX. BlackRock Inc. acquired a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $158,534,000. Jupiter Topco LLC bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $94,014,000. Janus Henderson Group PLC grew its holdings in shares of Amylyx Pharmaceuticals by 11.6% during the 1st quarter. Janus Henderson Group PLC now owns 4,986,073 shares of the company’s stock worth $69,257,000 after purchasing an additional 520,201 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $18,912,000. Finally, Almitas Capital LLC bought a new stake in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $17,509,000. 95.84% of the stock is currently owned by institutional investors.

Insider Activity at Amylyx Pharmaceuticals

In other news, insider Camille L. Bedrosian sold 10,028 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $32.40, for a total transaction of $324,907.20. Following the completion of the transaction, the insider owned 278,064 shares of the company’s stock, valued at approximately $9,009,273.60. This represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Gina Mazzariello sold 9,536 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $32.46, for a total transaction of $309,538.56. Following the completion of the sale, the insider owned 190,838 shares of the company’s stock, valued at approximately $6,194,601.48. The trade was a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 60,374 shares of company stock valued at $1,815,257. Company insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Company Profile